Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.

Abstract:

:One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12-15 months of age in the primary study (NCT00861744), were followed-up for 2 y post-vaccination. Anti-measles and anti-rubella antibodies were measured using Enzyme-Linked Immunosorbent Assay (ELISA), and anti-mumps antibodies using ELISA and plaque reduction neutralization (PRN) assays. Serious adverse events (SAEs) were recorded during the entire follow-up. The according-to-protocol (ATP) persistence cohort included 752 children (M-M-R II = 186, MMR-RIT = 566), who received primary vaccination at a mean age of 12.3 ( ± 0.67) months. 104 children were revaccinated with MMR-containing vaccines; therefore, serology results for timepoints after revaccination were excluded from the analysis. Seropositivity for measles (Year 1≥ 98.3%; Year 2≥ 99.4%) and rubella (Year 1≥ 98.9%; Year 2 = 100%) remained as high at Year 2 as at Day 42. Similarly, seropositivity for mumps determined by ELISA (Year 1≥ 90.1%; Year 2≥ 94.1%) and PRN assays (Year 1≥ 87.5%; Year 2≥ 91.7%) persisted. Thirty-three SAEs were recorded in 23 children; 2 SAEs (inguinal adenitis and idiopathic thrombocytopenic purpura) and one SAE (febrile convulsion) were considered as potentially related to MMR-RIT and M-M-R II, respectively. This study showed that antibodies against measles, mumps and rubella persisted for up to 2 y post-vaccination with either MMR vaccine in children aged 12-15 months, and that both vaccines were well-tolerated during the follow-up period.

journal_name

Hum Vaccin Immunother

authors

Berry AA,Abu-Elyazeed R,Diaz-Perez C,Mufson MA,Harrison CJ,Leonardi M,Twiggs JD,Peltier C,Grogg S,Carbayo A,Shapiro S,Povey M,Baccarini C,Innis BL,Henry O

doi

10.1080/21645515.2017.1309486

subject

Has Abstract

pub_date

2017-07-03 00:00:00

pages

1516-1522

issue

7

eissn

2164-5515

issn

2164-554X

journal_volume

13

pub_type

杂志文章,随机对照试验
  • Maintaining the momentum: key factors influencing acceptance of influenza vaccination among pregnant women following the H1N1 pandemic.

    abstract::This survey study compared pre- and post-pandemic knowledge, attitudes, beliefs, and intended behaviors of pregnant women regarding influenza vaccination (seasonal and/or pandemic) during pregnancy in order to determine key factors influencing their decision to adhere to influenza vaccine recommendations. Only 36% of ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/21645515.2014.980684

    authors: Halperin BA,MacKinnon-Cameron D,McNeil S,Kalil J,Halperin SA

    更新日期:2014-01-01 00:00:00

  • Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016).

    abstract::This article aims to explore the trends of monoclonal antibodies (mAbs) research and commercialization, mainly to examine the development trajectories by a contrastive exploration of successful and unsuccessful mAb. This work is based on two sets of R&D project reports, consisting of 517 discontinued mAb project repor...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1420445

    authors: Lai Y,Suo S,Wang R,Kong X,Hu Y,Tang D,Shi H,Chen S,Hu H

    更新日期:2018-04-03 00:00:00

  • Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.

    abstract::A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls an...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1403700

    authors: Moreira ED,Giuliano AR,de Hoon J,Iversen OE,Joura EA,Restrepo J,Van Damme P,Vandermeulen C,Ellison MC,Krick A,Shields C,Heiles B,Luxembourg A

    更新日期:2018-02-01 00:00:00

  • Utilization pattern of Haemophilus influenza type b vaccine in eight provinces of China.

    abstract:OBJECTIVE:In China, Hib vaccine is a private-sector vaccine that is an option for parents to select to give to their children; it must be paid for out-of-pocket because it is not included in the government's Expanded Program on Immunization (EPI). We evaluated utilization patterns of Hib vaccine to provide evidence in ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1420447

    authors: Li Y,Yue C,Wang Y,Zhu X,Martin K,Scherpbier RW,Liu J,Wang Z,Ma Y,Cheng H,Zhang Z,Wang Q,Li H,Xie S,Xiao Q,Wang H,An Z

    更新日期:2018-04-03 00:00:00

  • A monoclonal antibody to an abrin chimera recognizing a unique epitope on abrin A chain confers protection from abrin-induced lethality.

    abstract::Abrin, obtained from the seeds of Abrus precatorius plant, is a potent toxin belonging to the family of type II ribosome-inactivating proteins. Recently, a recombinant vaccine consisting of the A subunits of abrin and its homolog Abrus precatorius agglutinin (APA) was demonstrated to protect mice from abrin lethality....

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1067741

    authors: Kumar MS,Karande AA

    更新日期:2016-01-01 00:00:00

  • Influenza immunization during pregnancy: Benefits for mother and infant.

    abstract::The serious consequences of influenza infection during pregnancy have been recognized for almost a century. In this article, we reviewed the evidence on the immunogenicity, safety and impact of maternal influenza immunization for both mother and child. After vaccination, pregnant women have similar protective titers o...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1215392

    authors: Sakala IG,Honda-Okubo Y,Fung J,Petrovsky N

    更新日期:2016-12-01 00:00:00

  • Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population: The ESCULAPIO project.

    abstract::The ESCULAPIO Project aims at increasing awareness on vaccine preventable infectious diseases (VPID) and vaccinations in different target populations and to spread the culture of prevention. Information/training interventions on VPID have been developed and health promotion activities for the general population, stude...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1268008

    authors: Bechini A,Bonanni P,Lauri S,Tiscione E,Levi M,Prato R,Fortunato F,Martinelli D,Gasparini R,Panatto D,Amicizia D,Coppola RC,Pellizzari B,Tabacchi G,Costantino C,Vitale F,Iannazzo S,Boccalini S

    更新日期:2017-02-01 00:00:00

  • Maternal immunization. Clinical experiences, challenges, and opportunities in vaccine acceptance.

    abstract::Maternal immunization holds tremendous promise to improve maternal and neonatal health for a number of infectious conditions. The unique susceptibilities of pregnant women to infectious conditions, as well as the ability of maternally-derived antibody to offer vital neonatal protection (via placental transfer), togeth...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/21645515.2014.970901

    authors: Moniz MH,Beigi RH

    更新日期:2014-01-01 00:00:00

  • Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies?

    abstract::Control programs for emerging influenza are in urgent need of novel therapeutic strategies to mitigate potentially devastating threats from pathogenic strains with pandemic potential. Current vaccines and antivirals have inherent limitations in efficacy, especially with rapid evolutionary changes of influenza viruses....

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2017.1363135

    authors: Berry CM

    更新日期:2018-03-04 00:00:00

  • Key considerations for successful implementation of maternal immunization programs in low and middle income countries.

    abstract::The Maternal Neonatal Tetanus Elimination program is proof of concept for the feasibility and potential for maternal immunization to reduce neonatal mortality particularly in low and middle-income countries. Introduction of any additional vaccine into the antenatal space, such as Influenza and Pertussis, and potential...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1564433

    authors: Krishnaswamy S,Lambach P,Giles ML

    更新日期:2019-01-01 00:00:00

  • Willingness to pay for an Ebola vaccine during the 2014-2016 ebola outbreak in West Africa: Results from a U.S. National sample.

    abstract::The 2014-2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S. national sample during the recent Ebola outbreak. From April 30-May 8, 2015, a national survey was conducted u...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1423928

    authors: Painter JE,von Fricken ME,Viana de O Mesquita S,DiClemente RJ

    更新日期:2018-07-03 00:00:00

  • Titering of 2009 pandemic H1N1 influenza virus hemagglutinin inhibition antibody in nonvaccinated pregnant women in Shiraz, Southern Iran.

    abstract::Influenza may cause severe complications for pregnant women. In this study antibody response against 2009 H1N1 influenza virus in pregnant women was investigated. This seroprevalance cross sectional and questionnaire based study was conducted using a convenient sampling method. Blood samples of pregnant women were che...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.19189

    authors: Honarvar B,Moghadami M,Moattari A,Emami A,Tabatabaee HR,Jahromi BN,Asadi N,Mousavizadeh A,Lankarani KB,Joulaei H,Ghaffarpasand F

    更新日期:2012-05-01 00:00:00

  • Pertussis vaccination in pregnancy.

    abstract::Pertussis has had a resurgence with the highest incidence and complication rates in young infants, and deaths occurring mainly at < age 3 months. Infants are infected by older individuals whose immunity has waned. Strategies such as targeted immunization of infant caregivers have had limited success. Pertussis vaccina...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1171948

    authors: Healy CM

    更新日期:2016-08-02 00:00:00

  • Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.

    abstract::Italy was one of the first countries in the world to introduce a routine vaccination program against HBV for newborns and 12-y-old children. From a clinical point of view, such strategy was clearly successful. The objective of our study was to verify whether, at 20 y from its implementation, hepatitis B universal vacc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.23827

    authors: Boccalini S,Taddei C,Ceccherini V,Bechini A,Levi M,Bartolozzi D,Bonanni P

    更新日期:2013-05-01 00:00:00

  • A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection.

    abstract::The effective protective HIV vaccine should elicit either protective antibodies or effective T cell response, or both. To improve the efficacy of HIV-1 vaccines, HLA polymorphism and HIV-1 diversity are 2 key factors to be considered for vaccine development. In this study, we expressed a recombinant multi-epitope prot...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1281488

    authors: Yang Y,Zhu Q,Sun W,Guo J,Ning X,Li Q,Guo Y,Li J,Kou Z,Zhou Y

    更新日期:2017-06-03 00:00:00

  • Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons.

    abstract::Influenza vaccination aims at reducing the incidence of serious disease, complications and death among those with the most risk of severe influenza disease. Influenza vaccine effectiveness (VE) through sentinel surveillance data from the PIDIRAC program (Daily Acute Respiratory Infection Surveillance of Catalonia) dur...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.36155

    authors: Torner N,Martínez A,Basile L,Marcos MA,Antón A,Mar Mosquera M,Isanta R,Cabezas C,Jané M,Domínguez A,Program Of Catalonia TP

    更新日期:2015-01-01 00:00:00

  • Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.

    abstract::Rotavirus (RV) infection is the primary cause for childhood gastroenteritis worldwide. In Korea, RV infection is most common among children less than 5 years of age. This post-licensure study was conducted to further evaluate the RV vaccine (RIX4414) to provide additional local clinical data to the Korean Food and Dru...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/hv.19853

    authors: Kim JS,Bae CW,Lee KY,Park MS,Choi YY,Kim KN,Kim JD,Park WS,Sin JB,Kim EA,Lee SG,Kim CS,Cha SH,Hong YJ,Shin SM,Shim GH,Choi KM,Yang JW,Liu A,Suryakiran PV,Han HH

    更新日期:2012-06-01 00:00:00

  • Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.

    abstract::Typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), is a major health problem particularly in developing countries. The available vaccines have certain limitations regarding their efficacy, and inability to induce an immune response especially in individuals under 2 years of age. Conjugate vaccines ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.18350

    authors: Ali A,An SJ,Cui C,Haque A,Carbis R

    更新日期:2012-02-01 00:00:00

  • Public health responses during measles outbreaks in elimination settings: Strategies and challenges.

    abstract::In late September 2016, the Americas became the first region in the world to have eliminated endemic transmission of measles virus. Several other countries have also verified measles elimination, and countries in all six World Health Organization regions have adopted measles elimination goals. The public health strate...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1474310

    authors: Gastañaduy PA,Banerjee E,DeBolt C,Bravo-Alcántara P,Samad SA,Pastor D,Rota PA,Patel M,Crowcroft NS,Durrheim DN

    更新日期:2018-01-01 00:00:00

  • The first case of Kawasaki disease in a 20-month old baby following immunization with rotavirus vaccine and hepatitis A vaccine in China: A case report.

    abstract::Kawasaki disease (KD) after rotavirus and hepatitis A vaccination has not previously been reported in a baby in China. Herein, we describe a 20-month-old child who developed Kawasaki disease after receiving her second dose of Lanzhou lamb rotavirus vaccine (LLR) and her first dose of freeze-dried live attenuated hepat...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1050571

    authors: Yin S,Liubao P,Chongqing T,Xiaomin W

    更新日期:2015-01-01 00:00:00

  • Tetanus toxoid vaccine: elimination of neonatal tetanus in selected states of India.

    abstract::Tetanus is caused by a neurotoxin produced by Clostridium tetani (C. tetani), a spore-forming bacterium. Infection begins when tetanus spores are introduced into damaged tissue. Tetanus is characterized by muscle rigidity and painful muscle spasms caused by tetanus toxin's blockade of inhibitory neurons that normally ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.21145

    authors: Verma R,Khanna P

    更新日期:2012-10-01 00:00:00

  • Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

    abstract::Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors fo...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,实务指引,评审

    doi:10.1080/21645515.2016.1150396

    authors: Esposito S,Bonanni P,Maggi S,Tan L,Ansaldi F,Lopalco PL,Dagan R,Michel JP,van Damme P,Gaillat J,Prymula R,Vesikari T,Mussini C,Frank U,Osterhaus A,Celentano LP,Rossi M,Guercio V,Gavazzi G

    更新日期:2016-07-02 00:00:00

  • Anti-leukemia T cells in AML: TNF-α⁺ CD8⁺ T cells may escape detection and possibly reflect a stage of functional impairment.

    abstract::Leukemia-associated antigens such as proteinase-3 (PR3) and Wilms' tumor protein-1 (WT-1) are potential targets of T-cell responses, which can be monitored by T-cell assays within vaccination trials and after allogeneic stem cell transplantation (SCT). In chronic myeloid leukemia (CML) an aberrant cytokine profile of ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.24250

    authors: Flörcken A,van Lessen A,Terwey TH,Dörken B,Arnold R,Pezzutto A,Westermann J

    更新日期:2013-06-01 00:00:00

  • Impact of SA 14-14-2 vaccination on the occurrence of Japanese encephalitis in India.

    abstract::Japanese encephalitis virus is the major cause of encephalitis in India. To control the increasing incidence and fatal outbreaks, SA 14-14-2 vaccine was introduced initially in 104 endemic districts in phased manner from 2006 to 2011. As there is no data available before 2008 on the number of Japanese encephalitis (JE...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1564435

    authors: Muniaraj M,Rajamannar V

    更新日期:2019-01-01 00:00:00

  • Approaches to the vaccination of pregnant women: experience from Stockport, UK, with prenatal influenza.

    abstract::For the 2010/11 influenza season the prenatal vaccination program was extended to all women in England and Wales irrespective of gestational age--this was a considerable shift in practice for both pregnant women and healthcare providers where the emphasis previously had been only on targeted vaccination for pregnant w...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.25525

    authors: Baxter D

    更新日期:2013-06-01 00:00:00

  • Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.

    abstract::The prevalence of seasonal allergic rhinitis in the western world is high and increasing. Besides considerably affecting physical and psychosocial aspects of patients' lives, allergic rhinitis is often associated with allergic asthma and may aggravate this condition over time. Specific immunotherapy is currently the o...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.24631

    authors: Rosewich M,Lee D,Zielen S

    更新日期:2013-07-01 00:00:00

  • Novel dendritic cell-based vaccination in late stage melanoma.

    abstract::Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play an important role in stimulating an immune response of both CD4(+) T helper cells and CD8(+) cytotoxic T lymphocytes (CTLs). As such, DCs have been studied extensively in cancer immunotherapy for their capability to induce a specific anti...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.29110

    authors: Schneble EJ,Yu X,Wagner TE,Peoples GE

    更新日期:2014-01-01 00:00:00

  • Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.

    abstract::Salmonella enterica serovar Paratyphi A (S. Paratyphi A) is a human restricted pathogen that can cause systemic infection (paratyphoid fever) with recently increased incidence particularly in developing countries. Currently there is no licensed vaccine for prevention of infection from S. Paratyphi A. In this study the...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.28130

    authors: Ali A,An SJ,Cui C,Haque A,Carbis R

    更新日期:2014-01-01 00:00:00

  • Post-marketing surveillance study to assess the safety and tolerability of an Inactivated Poliomyelitis Vaccine in Indian children.

    abstract:OBJECTIVE:To evaluate the incidence of adverse events following administration of an Inactivated poliomyelitis vaccine (IPV) manufactured by Serum Institute of India Pvt. Ltd., Pune, India. METHODS:A single 0.5 ml dose of the IPV was administered intramuscularly to children attending private clinics or out-patient dep...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1356960

    authors: Sharma H,Dhere R,Parekh S,Shewale S

    更新日期:2017-11-02 00:00:00

  • Meningococcal vaccine: a new vaccine to combat meningococcal disease in India.

    abstract::Meningococcal meningitis is caused by Neisseria meningitidis, a gram-negative, aerobic, encapsulated diplococcus. Meningococci are divided into numerous serogroups based on the composition of their capsular polysaccharide (Ps) antigens. At least 13 serogroups have been described: A, B, C, D, 29E, H, I, K, L, W-135, X,...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.21666

    authors: Verma R,Khanna P

    更新日期:2012-12-01 00:00:00